Christine Kucera, MD
Allergy & Immunology · Oro Valley, AZNPI 1114924750
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 261 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AstraZeneca at 27.8% of the total.
Across 261 payments — averaging $26.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$835
- CSL Behring$697
- Sanofi$659
- Regeneron Healthcare Solutions, Inc.$285
- Sun Pharmaceutical Industries Inc.$244
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,81199%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $1,907 |
| GSK | 54 | $835 |
| CSL Behring | 27 | $697 |
| Sanofi | 18 | $659 |
| Regeneron Healthcare Solutions, Inc. | 13 | $285 |
| Sun Pharmaceutical Industries Inc. | 4 | $244 |
| Genentech USA, Inc. | 8 | $238 |
| Covis Pharma GmbH | 6 | $179 |
| Pfizer | 9 | $178 |
| Amgen | 6 | $176 |
| Pharming Healthcare, Inc. | 9 | $157 |
| Biocryst US Sales Co., LLC | 2 | $149 |
| Shire North American Group Inc | 3 | $144 |
| Kaleo, Inc. | 6 | $123 |
| Novartis | 7 | $114 |
| Teva Pharmaceuticals USA, Inc. | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $87 |
| Boehringer Ingelheim | 4 | $84 |
| Grifols USA, LLC | 4 | $69 |
| Optinose US, Inc. | 3 | $67 |
| AbbVie | 3 | $62 |
| Octapharma USA, Inc. | 2 | $59 |
| LEO Pharma Inc. | 1 | $50 |
| Almirall LLC | 2 | $38 |
| Circassia Inc. | 2 | $31 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $23 |
| Galderma Laboratories, L.p. | 1 | $22 |
| USWM, LLC | 1 | $19 |
| EPI Health, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,852 in reported general payments places this provider in the 65th percentile of 90 allergy & immunology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $91,641 |
| Arnuity ElliptaFluticasone Furoate | 57 | $27,287 |
| Qvar RedihalerBeclomethasone Dipropionate | 32 | $17,312 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $16,935 |
| Azelastine Hcl | 216 | $11,659 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $8,198 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $8,173 |
| Epinephrine | 54 | $7,566 |
| Pulmicort FlexhalerBudesonide | 12 | $5,266 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 168 | $3,816 |
| Montelukast Sodium | 262 | $3,224 |
| Ipratropium Bromide | 57 | $3,130 |
| Fluticasone Propionate | 110 | $2,926 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $2,608 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 16 | $2,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $835 | $127,100151 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $1,907 | $22,20049 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $113 | $17,31232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 90 allergy & immunology providers in Arizona.
Other allergy & immunology in Oro Valley
- David FriedmanOro Valley$11K
- Michael ManningScottsdale$1.1M
- Neal JainGilbert$388K
- Jennifer HillScottsdale$335K
- Jean NelsonScottsdale$183K
- Kiranjit KhalsaScottsdale$124K
- Keith SaccoPhoenix$118K
- Jacob MadduxSurprise$87K
- Tara CarrTucson$76K
- Duane WongChandler$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.